Palvella Therapeutics (PVLA) stock
PVLA's Quality Score fell 3 points on Fri, Nov 20, to -2. Its week-by-week trend stopped pointing up (2 chart checks stopped).
Follow PVLA's trial news. Pro members can get an alert when Palvella Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on PVLA
| Holding it back | 31.3% more shares than a year ago |
| Latest filing | 8-K, Nov 5 |
PVLA in the news
Big story
PVLA closed +11.0% that day on 1.7x normal volume.
PVLA catalysts
After its last 4 reports it closed +1.1% on average, higher 2 of 4 times.
What's next for PVLA, and how long its cash lasts
Next step the company has named
Cash runway
The company says its cash lasts into 2H 2027 (8-K, Jan 29).
Dilution on the horizon
- Shelf registration (S-3, filed Jan 2, 2026)
- At-the-market share sales program (S-3, filed Jan 2, 2026)
Insiders
Chief Scientific Officer Jeffrey S. Martini sold 12,500 shares on Nov 11, under a planned sale. 16 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Why PVLA scores -2
Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
Well below its recent run. PVLA scores -2 today, against a median of 5.5 over its last 20 recorded sessions.
- +2Long-term trend above a rising 200-day average
- −2Dilution 31.3% more shares outstanding than a year ago, from Massive's market data
- Chart checks adds
- Profit subtracts
- Volatility subtracts
- Cash flow subtracts
How PVLA ranks in Biotech
PVLA is #125 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 125 |
Cash and short-term investments: PVLA $237M, RCUS $630M, KNSA $569M, XNCR $378M.
When does PVLA report earnings, and what happens after?
Expected to report Wed Mar 31, before the open (in 130 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What PVLA reported on Nov 5, 2026
The quarter
The figures are not read from the release yet.
“The increase was primarily due to increased spending on manufacturing activities, the clinical development of QTORIN rapamycin for the treatment of angiokeratomas, costs associated with completion of the submission of the rolling NDA, and costs resulting from increased headcount and consulting services in 2026.”
Where the sales came from
PVLA's results filing gives no sales by line in a table we read.
The outlook
No outlook figures read from this release.
In the company's words
“The increase was primarily due to increased headcount in 2026, as well as increased professional services related to operating as a publicly-traded company.”
From its results filing (SEC filing · Nov 5)
The numbers
- $2.1B
- today
Close after the report, last 3
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | +2.7% | -3.4% | +1.0% |
| Aug 4, 2026 | -3.9% | +8.0% | +8.1% |
| May 7, 2026 | -0.9% | -13.0% | -7.4% |
PVLA has 1 of 14 chart checks firing
PVLA RSI on Nov 20: 45.9, above its 50-day and 200-day averages
RSI 45.9, MACD below signal, above both averages. Not scored.
The deep dive on PVLA
- What it does and how it makes moneySEC filing · Mar 29, 2024SEC filing · Mar 29, 2024
- Where it stands
- Who holds and trades it
- Against its closest peers
PVLA insider trades
One insider sold $49K across 1 filing in the last 6 months. No open-market buys on record. The newest:
PVLA's officers and directors
Officers and directors with a Form 4 in the last 12 months.
About Palvella Therapeutics
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would turn PVLA's score around: 8 things
- 8 more filings explained, a plain line each
- Real-time prices, no delay
Straight AnswersStraight Answers
What does PVLA's Quality Score say?
PVLA scores -2 today, which Breakaway calls Poor. It is #125 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is PVLA's Quality Score?
PVLA scores -2 today, which Breakaway calls Poor (below zero). That is #125 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PVLA's -2.
Are insiders buying PVLA?
One insider sold $49K across 1 filing in the last 6 months. No open-market buys on record. The newest is Christopher P. Kiritsy, Director, who sold $49K on Sep 2.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.